Tamoxifen (Citrate)
Tamoxifen (Citrate) Information

About Tamoxifen (Citrate)

Tamoxifen (Citrate) is a nonsteroidal antiestrogen, antineoplastic agent, chemically related to another antiestrogen, like clomiphene. It blocks estrogen at its receptor on the cell surface of cancer cells that require estrogen for growth and development. Tamoxifen (Citrate) is most often used as an adjunct to breast surgery in the treatment of breast cancer, can be used as sole therapy for metastatic breast cancer in women with estrogen-receptor positive. Tamoxifen (Citrate) is also used as an adjunct after surgical removal of a breast tumor, or in combination with chemotherapy for breast cancer. Tamoxifen was approved by the FDA in 1977 for use in patients with breast cancer. Tamoxifen (Citrate) is currently being investigated as an agent to reduce bone loss due to osteoporosis in post-menopausal women.

Indications

Tamoxifen (Citrate) is primarily indicated in conditions like Breast cancer, Infertility.

Contraindication

Tamoxifen (Citrate) is contraindicated in conditions like Hypersensitivity to the drug.

Side Effects

The severe or irreversible adverse effects of Tamoxifen (Citrate), which give rise to further complications include Cataract, Retinopathy, Cystic ovarian swelling.Tamoxifen (Citrate) produces potentially life-threatening effects which include Hypercalcemia. which are responsible for the discontinuation of Tamoxifen (Citrate) therapy.The symptomatic adverse reactions produced by Tamoxifen (Citrate) are more or less tolerable and if they become severe, they can be treated symptomatically, these include Pruritus, Fluid retention, Hot flushes, GI disturbance.

Warnings

Contraceptive (birth control) measures are recommended for use in men and women while taking tamoxifen. It is not recommended for use in pregnant or nursing women. If patient experience swelling around the ankles or legs, so should decrease salt intake.

High Risk Groups

Drug should not be given to Paediatrics, Pregnant Mothers, Geriatrics, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.